Adipose tissue expands via differentiation of preadipocytes into adipocytes (adipogenesis) and/or hypertrophy of existing adipocytes. A low adipogenic capacity promotes adipocyte hypertrophy, causing inflammatory macrophage accumulation and insulin resistance. Macrophage-conditioned medium (MacCM) inhibits adipogenesis and promotes adipocyte inflammation, but it is unknown if these effects are altered by high glucose (HG) versus normal glucose (NG) concentrations. The effect of HG on adipogenesis was assessed. Human subcutaneous abdominal preadipocytes were induced to differentiate in HG or NG conditions. HG did not affect adipogenesis. HG increased ChREBP-β mRNA and protein levels, and increased GLUT4 mRNA, in differentiated adipocytes. It did not change mRNA levels of ACC, SCD, and FAS. The increase in ChREBP-β mRNA was positively correlated with HG-induced increase in GLUT4 mRNA. The effect of HG-MacCM versus NG-MacCM on human adipogenesis and adipocyte inflammation was compared. Human monocyte-derived macrophages (MDM) were placed in NG or HG glucose for 24 hours to generate MacCM. HG-MacCM, but not NG-MacCM inhibited triacylglycerol accumulation and protein expression of PPARγ during human adipogenesis. Preadipocytes differentiated in HG-MacCM displayed a more pro-inflammatory phenotype, as assessed by increased MCP-1 and IL-6 and reduced adiponectin mRNA expression. HG increased phosphorylation of IKK-β and decreased protein expression of IκBα in MDMs. In addition, HG reduced protein expression of PPARγ in MDMs. The pro-inflammatory effect of HG-MacCM on MCP-1 expression in adipocytes was partially inhibited when MDMs were treated with sc-514 (IKKβ inhibitor). My data demonstrate that HG-induced expression of ChREBP-β in adipocytes may be associated with increased GLUT4 mRNA. The anti-adipogenic and pro-inflammatory effects of HG-MacCM are more potent than NG-MacCM. This suggests the possibility that adipose tissue cellular remodeling in vivo may be altered with hyperglycemia.

The preadipocyte is crucial for healthy adipose tissue (AT) remodeling, and insulin resistance in these cells may contribute to AT dysfunction. Chronic exposure to insulin and high glucose induces insulin resistance in the 3T3-L1 mouse adipocyte cell line in vitro, however, whether this occurs in human preadipocytes is not known. To investigate this, human preadipocytes were isolated from subcutaneous AT obtained from 6 female patients undergoing elective surgery (Research Ethics Board-approved). Human preadipocytes were incubated in 5 mM glucose or 25 mM glucose in the presence or absence of 0.6 nM insulin for 48 hours, followed by acute 100 nM insulin stimulation. 25 mM glucose + 0.6 nM insulin inhibited insulin-stimulated tyrosine phosphorylation of IR-β (77%) and IRS-1 (81%) compared to NG (p<0.01), however, insulin-stimulated Ser473 Akt phosphorylation was not affected. 25 mM glucose and/or 0.6 nM insulin did not significantly change levels of pro-inflammatory adipokines. 25 mM glucose and/or 0.6 nM, prior to and/or during 14 days of adipogenic induction, did not affect levels of adipogenic markers or intracellular triglyceride accumulation.

Adipositas und die damit verbundenen Begleiterkrankungen zeigen einen deutlichen Anstieg der Prävalenz in der Bevölkerung. Auch für die Schwangerschaft gilt starkes Übergewicht als Risikofaktor für metabolische und vaskuläre Komplikationen wie Gestationsdiabetes mellitus (GDM) und Präeklampsie (PE). In den letzten 20 Jahren wurde eindrücklich nachgewiesen, dass eine Dysregulation von Fettzell-sezernierten Proteinen, sogenannten Adipokinen, ursächlich zu GDM und PE beitragen könnte. Zu Beginn der Dissertation lagen jedoch nur unzureichende Daten über die Regulation des Insulinresistenz-induzierenden, anti-adipogenen und anti-angiogenen Adipokins Preadipocyte factor-1 (Pref-1) bei GDM und PE vor. Die vorliegende Arbeit untersucht daher die Regulation von zirkulierendem Pref-1 bei GDM und PE sowie seine Expression in der Plazenta. Bei 74 Patientinnen mit GDM konnte kein signifikanter Unterschied der Pref-1 Konzentrationen (0.40 µg/l) verglichen zu 74 Gesunden (0.42 µg/l) (p = 0.655) festgestellt werden (Wurst U et al., Cytokine 2015; 71: 161–164). Es zeigte sich in der Kohorte eine unabhängige Assoziation zwischen Pref-1 und Schwangerschaftsalter bei der Blutentnahme, Triglyzeriden, Kreatinin, Body Mass Index und C reaktivem Protein (p < 0.05). In einer Studienkohorte von 51 Schwangeren mit PE wurden signifikant niedrigere Serumspiegel von Pref-1 (0.49 µg/l) im Vergleich zu 51 gesunden Schwangeren (0.68 µg/l) (p < 0.001) gemessen (Schrey S, Wurst U, et al., Cytokine 2015; 75: 338–343). In der multiplen Regressionsanalyse waren PE, Schwangerschaftsalter zum Zeitpunkt der Blutentnahme sowie zirkulierendes Leptin unabhängige Prädiktoren für Pref-1. Im peripartalen Zeitraum zeigte sich ein akuter und deutlicher Abfall von zirkulierendem Pref-1 im mütterlichen Blut und das Adipokin wurde immunhistochemisch im Plazentagewebe nachgewiesen. Die Daten dieser Studien sind vereinbar mit den Hypothesen, dass Pref-1 mit fortschreitender Schwangerschaft zunehmend produziert wird, die Plazenta zur Sekretion des Adipokins aktiv beiträgt sowie das Adipokin bei PE dysreguliert ist. Weiterführende Untersuchungen im Tiermodell sowie prospektive Studien sind notwendig, um die Signifikanz von Pref-1 bei GDM und PE näher zu untersuchen.

Adipositas und die damit verbundenen Begleiterkrankungen zeigen einen deutlichen Anstieg der Prävalenz in der Bevölkerung. Auch für die Schwangerschaft gilt starkes Übergewicht als Risikofaktor für metabolische und vaskuläre Komplikationen wie Gestationsdiabetes mellitus (GDM) und Präeklampsie (PE). In den letzten 20 Jahren wurde eindrücklich nachgewiesen, dass eine Dysregulation von Fettzell-sezernierten Proteinen, sogenannten Adipokinen, ursächlich zu GDM und PE beitragen könnte. Zu Beginn der Dissertation lagen jedoch nur unzureichende Daten über die Regulation des Insulinresistenz-induzierenden, anti-adipogenen und anti-angiogenen Adipokins Preadipocyte factor-1 (Pref-1) bei GDM und PE vor. Die vorliegende Arbeit untersucht daher die Regulation von zirkulierendem Pref-1 bei GDM und PE sowie seine Expression in der Plazenta. Bei 74 Patientinnen mit GDM konnte kein signifikanter Unterschied der Pref-1 Konzentrationen (0.40 µg/l) verglichen zu 74 Gesunden (0.42 µg/l) (p = 0.655) festgestellt werden (Wurst U et al., Cytokine 2015; 71: 161–164). Es zeigte sich in der Kohorte eine unabhängige Assoziation zwischen Pref-1 und Schwangerschaftsalter bei der Blutentnahme, Triglyzeriden, Kreatinin, Body Mass Index und C reaktivem Protein (p < 0.05). In einer Studienkohorte von 51 Schwangeren mit PE wurden signifikant niedrigere Serumspiegel von Pref-1 (0.49 µg/l) im Vergleich zu 51 gesunden Schwangeren (0.68 µg/l) (p < 0.001) gemessen (Schrey S, Wurst U, et al., Cytokine 2015; 75: 338–343). In der multiplen Regressionsanalyse waren PE, Schwangerschaftsalter zum Zeitpunkt der Blutentnahme sowie zirkulierendes Leptin unabhängige Prädiktoren für Pref-1. Im peripartalen Zeitraum zeigte sich ein akuter und deutlicher Abfall von zirkulierendem Pref-1 im mütterlichen Blut und das Adipokin wurde immunhistochemisch im Plazentagewebe nachgewiesen. Die Daten dieser Studien sind vereinbar mit den Hypothesen, dass Pref-1 mit fortschreitender Schwangerschaft zunehmend produziert wird, die Plazenta zur Sekretion des Adipokins aktiv beiträgt sowie das Adipokin bei PE dysreguliert ist. Weiterführende Untersuchungen im Tiermodell sowie prospektive Studien sind notwendig, um die Signifikanz von Pref-1 bei GDM und PE näher zu untersuchen.

Macrophage-conditioned medium (MacCM) inhibits the differentiation of rodent and human preadipocytes. Previous studies report that murine J774A.1-MacCM inhibits clonal expansion (early required phase of adipogenesis), including Rb phosphorylation. I hypothesized that MacCM induced alterations in cyclins and/or cyclin-dependent kinases (CDKs) were responsible for impairing Rb phosphorylation. My first objective was to assess the effect of J774A.1-MacCM on CDK4, CDK2, and their regulatory cyclins. Murine 3T3-L1 preadipocytes were differentiated with control medium or J774A.1-MacCM. Expression of cyclin D and A was inhibited by J774A.1-MacCM. Inhibition of cyclin A expression was associated with reduced differentiation-induced CDK2 activity. My second objective was to assess the expression patterns of cell cycle proteins in differentiating human abdominal subcutaneous preadipocytes, which do not undergo clonal expansion in culture. Cyclin E expression increased with differentiation. THP-1-MacCM (a human macrophage cell line) further enhanced this increase. My studies suggest MacCM leads to alterations in cyclin/CDK regulation during adipogenesis in murine and human preadipocyte models.

The CCAAT/Enhancer Binding Protein Beta (C/EBPβ) is part of the leucine zipper family of transcription factors and is involved in a myriad of processes including cellular proliferation and differentiation. C/EBPβ is expressed as three isoforms (LAP*, LAP, LIP), translated from a single mRNA by a leaky ribosomal scanning mechanism. While LAP* and LAP have activating functions, LIP is recognized as being a repressor of transcription due to its lack of activation domains. Numerous studies have shown that C/EBPβ acetylation state modulates its activity in a promoter-specific manner. For instance, the acetyltransferases GCN5/PCAF and the deacetylase complex mSin3A/HDAC1 regulate C/EBPβ activity on the C/EBPa promoter. GCN5/PCAF-mediated acetylation of C/EBPβ was shown to positively affect its transcriptional activity in a steroid-dependent mechanism via the glucocorticoid receptor (GR). GR relieves HDAC1 association from C/EBPβ by targeting the deacetylase for proteasomal degradation, hence favouring GCN5-mediated acetylation of C/EBPβ and allowing maximum activation capacity to be reached. In order to further elucidate C/EBPβ activation, I sought to characterize the interplay between GCN5 and HDAC1 in regulating C/EBPβ LAP/LIP activity during murine adipogenesis by identifying their binding domain in C/EBPβ. I identified a minimal domain located within regulatory domain 1 (RD1) of C/EBPβ that is required for both GCN5 and HDAC1 binding. Furthermore, the loss of the identified domain in C/EBPβ appears to partially mimic the GR effect, thus giving C/EBPβ a higher basal transcriptional activity that accelerates NIH 3T3 and 3T3 L1 adipogenesis. Moreover, I also showed that the LIP isoform inhibitory mode of action is partially mediated through the mSin3A/HDAC1 repressor complex, which gives LIP an active repressor function. In addition to LIP inhibitory function, I also showed that a cysteine residue located in LAP* negatively regulates its transactivating function during murine adipogenesis. Although RD1 of C/EBPβ has been suggested to act as a negative regulatory domain, I showed that only five residues are responsible for most of its inhibitory effect. Hence, in an attempt to further define sub-domains within RD1, I characterized a new positive regulatory domain at its N-terminal region, which seems to be required for C/EBPβ activity in a promoter-specific manner. In conclusion, this study not only supports previously hypothesized mechanisms by which C/EBPβ is regulated, but it also redefines the contribution of LAP*, LAP and LIP in regulating transcription. Most importantly, the results emphasize the countless possibilities by which C/EBPβ transactivation potential could be modulated during cellular differentiation.

Macrophage-conditioned medium (MacCM) inhibits the differentiation of rodent and human preadipocytes. Previous studies report that murine J774A.1-MacCM inhibits clonal expansion (early required phase of adipogenesis), including Rb phosphorylation. I hypothesized that MacCM induced alterations in cyclins and/or cyclin-dependent kinases (CDKs) were responsible for impairing Rb phosphorylation. My first objective was to assess the effect of J774A.1-MacCM on CDK4, CDK2, and their regulatory cyclins. Murine 3T3-L1 preadipocytes were differentiated with control medium or J774A.1-MacCM. Expression of cyclin D and A was inhibited by J774A.1-MacCM. Inhibition of cyclin A expression was associated with reduced differentiation-induced CDK2 activity. My second objective was to assess the expression patterns of cell cycle proteins in differentiating human abdominal subcutaneous preadipocytes, which do not undergo clonal expansion in culture. Cyclin E expression increased with differentiation. THP-1-MacCM (a human macrophage cell line) further enhanced this increase. My studies suggest MacCM leads to alterations in cyclin/CDK regulation during adipogenesis in murine and human preadipocyte models.

The CCAAT/Enhancer Binding Protein Beta (C/EBPβ) is part of the leucine zipper family of transcription factors and is involved in a myriad of processes including cellular proliferation and differentiation. C/EBPβ is expressed as three isoforms (LAP*, LAP, LIP), translated from a single mRNA by a leaky ribosomal scanning mechanism. While LAP* and LAP have activating functions, LIP is recognized as being a repressor of transcription due to its lack of activation domains. Numerous studies have shown that C/EBPβ acetylation state modulates its activity in a promoter-specific manner. For instance, the acetyltransferases GCN5/PCAF and the deacetylase complex mSin3A/HDAC1 regulate C/EBPβ activity on the C/EBPa promoter. GCN5/PCAF-mediated acetylation of C/EBPβ was shown to positively affect its transcriptional activity in a steroid-dependent mechanism via the glucocorticoid receptor (GR). GR relieves HDAC1 association from C/EBPβ by targeting the deacetylase for proteasomal degradation, hence favouring GCN5-mediated acetylation of C/EBPβ and allowing maximum activation capacity to be reached. In order to further elucidate C/EBPβ activation, I sought to characterize the interplay between GCN5 and HDAC1 in regulating C/EBPβ LAP/LIP activity during murine adipogenesis by identifying their binding domain in C/EBPβ. I identified a minimal domain located within regulatory domain 1 (RD1) of C/EBPβ that is required for both GCN5 and HDAC1 binding. Furthermore, the loss of the identified domain in C/EBPβ appears to partially mimic the GR effect, thus giving C/EBPβ a higher basal transcriptional activity that accelerates NIH 3T3 and 3T3 L1 adipogenesis. Moreover, I also showed that the LIP isoform inhibitory mode of action is partially mediated through the mSin3A/HDAC1 repressor complex, which gives LIP an active repressor function. In addition to LIP inhibitory function, I also showed that a cysteine residue located in LAP* negatively regulates its transactivating function during murine adipogenesis. Although RD1 of C/EBPβ has been suggested to act as a negative regulatory domain, I showed that only five residues are responsible for most of its inhibitory effect. Hence, in an attempt to further define sub-domains within RD1, I characterized a new positive regulatory domain at its N-terminal region, which seems to be required for C/EBPβ activity in a promoter-specific manner. In conclusion, this study not only supports previously hypothesized mechanisms by which C/EBPβ is regulated, but it also redefines the contribution of LAP*, LAP and LIP in regulating transcription. Most importantly, the results emphasize the countless possibilities by which C/EBPβ transactivation potential could be modulated during cellular differentiation.

Macrophage-conditioned medium (MacCM) inhibits the differentiation of rodent and human preadipocytes. Previous studies report that murine J774A.1-MacCM inhibits clonal expansion (early required phase of adipogenesis), including Rb phosphorylation. I hypothesized that MacCM induced alterations in cyclins and/or cyclin-dependent kinases (CDKs) were responsible for impairing Rb phosphorylation. My first objective was to assess the effect of J774A.1-MacCM on CDK4, CDK2, and their regulatory cyclins. Murine 3T3-L1 preadipocytes were differentiated with control medium or J774A.1-MacCM. Expression of cyclin D and A was inhibited by J774A.1-MacCM. Inhibition of cyclin A expression was associated with reduced differentiation-induced CDK2 activity. My second objective was to assess the expression patterns of cell cycle proteins in differentiating human abdominal subcutaneous preadipocytes, which do not undergo clonal expansion in culture. Cyclin E expression increased with differentiation. THP-1-MacCM (a human macrophage cell line) further enhanced this increase. My studies suggest MacCM leads to alterations in cyclin/CDK regulation during adipogenesis in murine and human preadipocyte models.

The CCAAT/Enhancer Binding Protein Beta (C/EBPβ) is part of the leucine zipper family of transcription factors and is involved in a myriad of processes including cellular proliferation and differentiation. C/EBPβ is expressed as three isoforms (LAP*, LAP, LIP), translated from a single mRNA by a leaky ribosomal scanning mechanism. While LAP* and LAP have activating functions, LIP is recognized as being a repressor of transcription due to its lack of activation domains. Numerous studies have shown that C/EBPβ acetylation state modulates its activity in a promoter-specific manner. For instance, the acetyltransferases GCN5/PCAF and the deacetylase complex mSin3A/HDAC1 regulate C/EBPβ activity on the C/EBPa promoter. GCN5/PCAF-mediated acetylation of C/EBPβ was shown to positively affect its transcriptional activity in a steroid-dependent mechanism via the glucocorticoid receptor (GR). GR relieves HDAC1 association from C/EBPβ by targeting the deacetylase for proteasomal degradation, hence favouring GCN5-mediated acetylation of C/EBPβ and allowing maximum activation capacity to be reached. In order to further elucidate C/EBPβ activation, I sought to characterize the interplay between GCN5 and HDAC1 in regulating C/EBPβ LAP/LIP activity during murine adipogenesis by identifying their binding domain in C/EBPβ. I identified a minimal domain located within regulatory domain 1 (RD1) of C/EBPβ that is required for both GCN5 and HDAC1 binding. Furthermore, the loss of the identified domain in C/EBPβ appears to partially mimic the GR effect, thus giving C/EBPβ a higher basal transcriptional activity that accelerates NIH 3T3 and 3T3 L1 adipogenesis. Moreover, I also showed that the LIP isoform inhibitory mode of action is partially mediated through the mSin3A/HDAC1 repressor complex, which gives LIP an active repressor function. In addition to LIP inhibitory function, I also showed that a cysteine residue located in LAP* negatively regulates its transactivating function during murine adipogenesis. Although RD1 of C/EBPβ has been suggested to act as a negative regulatory domain, I showed that only five residues are responsible for most of its inhibitory effect. Hence, in an attempt to further define sub-domains within RD1, I characterized a new positive regulatory domain at its N-terminal region, which seems to be required for C/EBPβ activity in a promoter-specific manner. In conclusion, this study not only supports previously hypothesized mechanisms by which C/EBPβ is regulated, but it also redefines the contribution of LAP*, LAP and LIP in regulating transcription. Most importantly, the results emphasize the countless possibilities by which C/EBPβ transactivation potential could be modulated during cellular differentiation.